Biosense Webster Receives FDA Approval for Multiple Atrial Fibrillation Ablation Products to be Used in a Workflow Without Fluoroscopy
First and only AFib ablation products to receive approval for use in a workflow without fluoroscopy from the U.S. Food and Drug Administration. Enables workflows with zero fluoroscopy during catheter ablation procedures. The approval is based on data from REAL AF Registry, demonstrating value of real-world evidence
